Jounce Appoints Kim Drapkin, CPA As Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, today announced the appointment of Kim Drapkin, CPA to the position of chief financial officer. Ms. Drapkin brings to Jounce more than 20 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital and leading strategic financial planning.

"Kim's extensive financial leadership experience at all stages of growth will be extremely valuable as we continue building Jounce into a leading cancer immunotherapy company"

"Kim's extensive financial leadership experience at all stages of growth will be extremely valuable as we continue building Jounce into a leading cancer immunotherapy company," said Richard Murray Ph.D., chief executive officer of Jounce. "She has worked with Jounce since it's inception, playing a key role in building our financial infrastructure, and comes into this role with an already deep understanding of our strategy and culture. We are delighted to have Kim as a formal part of the Jounce leadership team."

"Immunotherapy has the potential to revolutionize cancer treatment and provide patients with more durable treatment options," said Ms. Drapkin. "Jounce's unique translational science and patient selection approach coupled with a strong team of experienced drug hunters distinguishes it in the industry. I'm delighted to be part of this great team focused on making a meaningful difference in the lives of patients."

Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early stage biotechnology companies, including Jounce. Additional clients included Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals and Voyager Therapeutics, Inc. In this role she helped early stage companies establish their financial infrastructure, manage financial strategy and operations, raise capital, build relationships with the financial community, and oversaw all other financial activities. Previously Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms. Drapkin was at Millennium Pharmaceuticals where she spent ten years in roles of increasing responsibility within the finance organization. Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin received her B.S. in accounting from Babson College.

About Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce integrates translational science insights to select the right targets and patient populations leading to clinical trials with higher probability of success and rapid proof-of-concept. The company is advancing programs that leverage contributions from its world-class founders as well as knowledge acquired from Jounce's translational science platform to create a sustainable "discovery to human proof-of-concept" product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Pure Communications, Inc.
Dan Budwick, 973-271-6085
[email protected]

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.